116 related articles for article (PubMed ID: 37984417)
1. A population pharmacokinetic model of methotrexate in Korean patients with haematologic malignancy.
Jung YS; Son M; Lee SG; Chong JW; Kim SJ; Jang JE; Lyu CJ; Hahn SM; Han JW; Park K
Br J Clin Pharmacol; 2024 Mar; 90(3):849-862. PubMed ID: 37984417
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic model of levetiracetam in Korean neonates with seizures
.
Jung YS; Lee SM; Park MS; Park K
Int J Clin Pharmacol Ther; 2018 May; 56(5):217-223. PubMed ID: 29393846
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics of Intravenous Methotrexate in Patients with Hematological Malignancies: Utilization of Routine Clinical Monitoring Parameters.
Nader A; Zahran N; Alshammaa A; Altaweel H; Kassem N; Wilby KJ
Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):221-228. PubMed ID: 27059845
[TBL] [Abstract][Full Text] [Related]
4. A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma.
Johansson ÅM; Hill N; Perisoglou M; Whelan J; Karlsson MO; Standing JF
Ther Drug Monit; 2011 Dec; 33(6):711-8. PubMed ID: 22105588
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.
Aumente D; Buelga DS; Lukas JC; Gomez P; Torres A; García MJ
Clin Pharmacokinet; 2006; 45(12):1227-38. PubMed ID: 17112298
[TBL] [Abstract][Full Text] [Related]
6. Vancomycin population pharmacokinetics and dosing recommendations in haematologic malignancy with augmented renal clearance children.
Lv CL; Lu JJ; Chen M; Zhang R; Li QC; Chen YY; Liu TT
J Clin Pharm Ther; 2020 Dec; 45(6):1278-1287. PubMed ID: 32557716
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic model and dosing optimization of vancomycin in hematologic malignancies with neutropenia and augmented renal clearance.
Belabbas T; Yamada T; Egashira N; Hirota T; Suetsugu K; Mori Y; Kato K; Akashi K; Ieiri I
J Infect Chemother; 2023 Apr; 29(4):391-400. PubMed ID: 36682608
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia.
Medellin-Garibay SE; Hernández-Villa N; Correa-González LC; Morales-Barragán MN; Valero-Rivera KP; Reséndiz-Galván JE; Ortiz-Zamudio JJ; Milán-Segovia RDC; Romano-Moreno S
Cancer Chemother Pharmacol; 2020 Jan; 85(1):21-31. PubMed ID: 31673826
[TBL] [Abstract][Full Text] [Related]
9. ABCB1 C3435T genetic polymorphism on population pharmacokinetics of methotrexate after hematopoietic stem cell transplantation in Korean patients: a prospective analysis.
Kim IW; Yun HY; Choi B; Han N; Park SY; Lee ES; Oh JM
Clin Ther; 2012 Aug; 34(8):1816-26. PubMed ID: 22796246
[TBL] [Abstract][Full Text] [Related]
10. Understanding hemoglobin contribution to high-dose methotrexate disposition-population pharmacokinetics in pediatric patients with hematological malignancies.
Škorić B; Jovanović M; Kuzmanović M; Miljković B; Vučićević K
Eur J Clin Pharmacol; 2024 May; 80(5):697-705. PubMed ID: 38347227
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia.
Gao X; Qian XW; Zhu XH; Yu Y; Miao H; Meng JH; Jiang JY; Wang HS; Zhai XW
Front Pharmacol; 2021; 12():701452. PubMed ID: 34326772
[TBL] [Abstract][Full Text] [Related]
12. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma.
Colom H; Farré R; Soy D; Peraire C; Cendros JM; Pardo N; Torrent M; Domenech J; Mangues MA
Ther Drug Monit; 2009 Feb; 31(1):76-85. PubMed ID: 19077931
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients.
Arshad U; Taubert M; Seeger-Nukpezah T; Ullah S; Spindeldreier KC; Jaehde U; Hallek M; Fuhr U; Vehreschild JJ; Jakob C
BMC Cancer; 2021 Jun; 21(1):719. PubMed ID: 34147089
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of intravenous dexmedetomidine in healthy Korean subjects.
Lee S; Kim BH; Lim K; Stalker D; Wisemandle W; Shin SG; Jang IJ; Yu KS
J Clin Pharm Ther; 2012 Dec; 37(6):698-703. PubMed ID: 22650799
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
Narwal R; Roskos LK; Robbie GJ
Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
18. High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy.
Min Y; Qiang F; Peng L; Zhu Z
Biopharm Drug Dispos; 2009 Nov; 30(8):437-47. PubMed ID: 19746402
[TBL] [Abstract][Full Text] [Related]
19. [Population pharmacokinetics of high-dose methotrexate administered in 329 children with acute lymphoblastic leukemia].
Zhang CY; Gu J; Li YZ; Lu W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):106-10. PubMed ID: 18315911
[TBL] [Abstract][Full Text] [Related]
20. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
Fabre MA; Fuseau E; Ficheux H
J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
